TGTX (TG Therapeutics) Short Interest


TGTX TG Therapeutics Inc TGTX
82 GF Score
Price $53.60
GF Value $58.08
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is TG Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

TGTX vs SRRK, COGT, RYTM: Short Interest Comparison

For the Biotechnology subindustry, TG Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TG Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TG Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where TG Therapeutics's Short Interest falls into.


TGTX
82GF Score
TG Therapeutics Inc TGTX
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is TG Therapeutics (TGTX) Overvalued in 2026?

Based on GuruFocus' analysis, TG Therapeutics stock appears to be undervalued. The current stock price of $53.60 is trading 7.7% below its estimated GF Value™ of $58.08. GuruFocus considers TG Therapeutics to be Fairly Valued.

Key valuation signals for TGTX:

  • Short Interest:
  • GF Value™: $58.08 vs. price of $53.60 (7.7% below fair value)
  • GF Score™: 82/100 with 7 warning signs

No single metric tells the full story. See the TGTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TG Therapeutics Business Description

Other Exchanges 1TGTX:ItalyNKB2:Germany
Address 3020 Carrington Mill Boulevard, Suite 475, Morrisville, NC, USA, 27560
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
82GF Score

Get the complete analysis for TGTX

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$53.60
Price
$58.08
GF Value